Compare Wegovy and Mounjaro: Evidence-Based UK Analysis
Is Wegovy or Mounjaro Better for Prescription Weight Loss?
When evaluating whether Wegovy or Mounjaro is better suited for prescription weight loss, the answer depends on individual medical factors rather than one treatment being universally superior. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, whilst Mounjaro utilises tirzepatide, which acts on both GIP and GLP-1 receptors as a dual agonist. This fundamental difference in mechanism means your prescriber will consider your medical history, current medications, and treatment goals when determining suitability.
Both medications require prescription-only access through licensed healthcare providers and must be used alongside a reduced-calorie diet and increased physical activity. EverydayMeds stocks both treatments through our GPhC-registered pharmacy (#9012878), ensuring you receive authentic, temperature-controlled medication regardless of which option your clinician recommends. The question of whether Wegovy or Mounjaro is better ultimately becomes a personalised clinical decision based on your unique circumstances.
Wegovy vs Mounjaro Pricing: UK Prescription Costs Compared
Understanding the cost difference when comparing whether Wegovy or Mounjaro is better requires examining each treatment's pricing structure. Wegovy follows a five-stage dose escalation starting at £79.99 for the initial 0.25mg pen, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of 2.4mg at £209.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Our bundle options provide convenient supply continuity, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Ultimate Stability Trio offering three months of 2.4mg maintenance supply for £649.99. These bundles prioritise convenience and Reliable Supply rather than individual savings. Both Wegovy and Mounjaro require similar dose escalation periods, so comparing long-term costs alongside clinical effectiveness helps determine which represents better value for your specific treatment journey.
Clinical Evidence: Wegovy vs Mounjaro Weight Loss Trials
The clinical evidence supporting both treatments comes from separate trial programmes with different designs, making direct comparison challenging when determining if Wegovy or Mounjaro is better. Wegovy's STEP trial programme demonstrated significant results, with STEP 1 showing approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, as reported by Wilding et al. in the New England Journal of Medicine, 2021. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events.
Mounjaro's SURMOUNT trials evaluated tirzepatide specifically for weight management, showing its dual-receptor mechanism may offer different benefits. However, comparing percentage weight loss figures between these programmes isn't clinically meaningful due to varying study populations, endpoints, and methodologies. Your prescriber can evaluate which trial evidence aligns better with your health profile when considering whether Wegovy or Mounjaro represents the optimal choice.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Understanding Wegovy's mechanism helps clarify why it might be considered when evaluating if Wegovy or Mounjaro is better for your needs. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone naturally produced in your intestines after eating. This hormone signals satiety to your brain, reducing appetite and promoting feelings of fullness after smaller meals. The once-weekly injection maintains consistent hormone levels, potentially reducing food cravings by acting on brain appetite centres. Unlike Mounjaro's dual-receptor approach, Wegovy's focused GLP-1 action provides a well-established pathway with extensive clinical data supporting its weight management effects.
UK Ordering Process: Getting Wegovy Through EverydayMeds
Whether you've decided Wegovy is better than Mounjaro for your situation, or your prescriber has recommended it following consultation, ordering through EverydayMeds follows a streamlined three-step process. Begin with our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review applications within three working days (24-hour express option available), ensuring thorough clinical oversight before approving your prescription-only medicine. Once approved, we dispatch your Wegovy via next-day delivery using cold-chain transportation to maintain the required 2-8°C temperature throughout transit. This ensures your medication arrives in optimal condition, whether you're starting the 0.25mg initial dose or continuing your established regimen.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements present one practical difference when determining if Wegovy or Mounjaro is better suited to your lifestyle. Wegovy offers superior room temperature tolerance, remaining stable for up to six weeks below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage proves particularly valuable for travel, work situations, or households with limited refrigeration space. The FlexTouch pen delivery system provides consistent dosing through its pre-loaded design, whilst the mandatory dose escalation schedule (0.25mg→0.5mg→1mg→1.7mg→2.4mg) allows your body to adjust gradually. Both treatments require similar injection techniques and storage vigilance, but Wegovy's extended room temperature stability offers additional flexibility for active lifestyles.
Comparing Mechanisms: Single vs Dual Receptor Targeting
The pharmacological difference between Wegovy and Mounjaro represents a key consideration when evaluating which might be better for prescription weight loss outcomes. Wegovy's semaglutide targets GLP-1 receptors exclusively, providing a focused approach with extensive real-world data spanning several years of clinical use. This established profile allows prescribers to predict response patterns and manage side effects based on substantial experience with GLP-1 agonist therapy.
Mounjaro's tirzepatide operates through dual GIP and GLP-1 receptor agonism, potentially offering enhanced glucose control alongside weight management effects. However, this dual mechanism introduces additional complexity in predicting individual responses and managing potential interactions. The question of whether Wegovy or Mounjaro is better often depends on whether you prioritise the established GLP-1 pathway or the theoretical advantages of dual-receptor targeting, balanced against your specific medical profile and treatment history.
Start Your Prescription Weight Loss Journey Today
Rather than continuing to wonder whether Wegovy or Mounjaro is better, taking action through professional assessment provides the answers you need for successful weight management. EverydayMeds offers both treatments through our GPhC-registered pharmacy (#9012878), ensuring you receive the option your prescriber determines most suitable for your individual circumstances. New customers can use discount code FIRST40 during checkout, whilst existing patients apply DOSE25 for continued savings. Our clinical team provides ongoing support throughout your treatment journey, whether you start with Wegovy's proven GLP-1 approach or your prescriber recommends Mounjaro's dual-receptor mechanism. Begin your 3-minute assessment today at https://everydaymeds.co.uk/collections/wegovy and discover which prescription weight loss solution offers the best path forward for your health goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
